start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=2
article-no=
start-page=127
end-page=129
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2006
dt-pub=20060901
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Localization of nonpalpable breast cancers using VATS marking system under ultrasonographic guidance
kn-title=非触知乳癌におけるVATSマーカーを用いたエコーガイド下マーキングの有用性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A preoperative tumor guiding system for nonpalpable breast cancer using a VATS guiding needle (Hakko Co., Ltd., Tokyo Japan) was reported. It was easy to introduce the guiding needle into breast cancers smaller than 1cm under
ultrasonographic observation. Neither bleeding nor infection was experienced. Wound management was easy and painless. This guiding system is very useful for locating and managing nonpalpable breast cancers even in outpatient
settings.
en-copyright=
kn-copyright=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=1
ORCID=
en-aut-name=TabuchiYoko
en-aut-sei=Tabuchi
en-aut-mei=Yoko
kn-aut-name=田渕陽子
kn-aut-sei=田渕
kn-aut-mei=陽子
aut-affil-num=2
ORCID=
en-aut-name=ItoMitsuya
en-aut-sei=Ito
en-aut-mei=Mitsuya
kn-aut-name=伊藤充矢
kn-aut-sei=伊藤
kn-aut-mei=充矢
aut-affil-num=3
ORCID=
en-aut-name=OnoRyoko
en-aut-sei=Ono
en-aut-mei=Ryoko
kn-aut-name=小野亮子
kn-aut-sei=小野
kn-aut-mei=亮子
aut-affil-num=4
ORCID=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=今田孝子
kn-aut-sei=今田
kn-aut-mei=孝子
aut-affil-num=5
ORCID=
en-aut-name=MatsukawaHiroyosi
en-aut-sei=Matsukawa
en-aut-mei=Hiroyosi
kn-aut-name=松川啓義
kn-aut-sei=松川
kn-aut-mei=啓義
aut-affil-num=6
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=7
ORCID=
en-aut-name=NaomotoYoshio
en-aut-sei=Naomoto
en-aut-mei=Yoshio
kn-aut-name=猶本良夫
kn-aut-sei=猶本
kn-aut-mei=良夫
aut-affil-num=8
ORCID=
en-aut-name=KanazawaSusumu
en-aut-sei=Kanazawa
en-aut-mei=Susumu
kn-aut-name=金澤右
kn-aut-sei=金澤
kn-aut-mei=右
aut-affil-num=9
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=2
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=3
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=4
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=5
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=6
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=7
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=8
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=9
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 放射線科
en-keyword=非触知乳癌 (nonpalpable breast cancer)
kn-keyword=非触知乳癌 (nonpalpable breast cancer)
en-keyword=マーキング (marking)
kn-keyword=マーキング (marking)
en-keyword=エコーガイド (guiding echo)
kn-keyword=エコーガイド (guiding echo)
en-keyword=VATS マーカー (VATS marker)
kn-keyword=VATS マーカー (VATS marker)
END
start-ver=1.4
cd-journal=joma
no-vol=124
cd-vols=
no-issue=3
article-no=
start-page=243
end-page=247
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2012
dt-pub=20121203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=A case of intracystic carcinoma of the breast showing pathological complete response by neoadjuvant chemotherapy
kn-title=術前化学療法により壁が菲薄化し組織学的寛解(pCR)となった巨大嚢胞内乳癌の1例
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= A 31-year-old woman presented to our hospital because of a lump 5cm in diameter in her right breast. Ultrasonography revealed a multilocular cystic mass with partial thickening of the wall and the septum. Core needle biopsy (CNB) of the septum confirmed invasive ductal carcinoma. The patient was administered neoadjuvant chemotherapy consisting of 12 cycles of weekly paclitaxel followed by 4 cycles of FEC (5FU, Epilubicin and cyclophosphamide). While the thickness of the wall and septum became thinner, the tumor size did not change in diameter. She underwent right mastectomy and sentinel node biopsy. Post-surgical histopathological findings showed a pathological complete response (pCR).
We report a rare case of invasive ductal carcinoma presenting a multilobular phenotype which showed pCR by neoadjuvant chemotherapy despite no size reduction of the tumor.
en-copyright=
kn-copyright=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=今田孝子
kn-aut-sei=今田
kn-aut-mei=孝子
aut-affil-num=1
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=2
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=3
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=岩本高行
kn-aut-sei=岩本
kn-aut-mei=高行
aut-affil-num=4
ORCID=
en-aut-name=OomoriMasako
en-aut-sei=Oomori
en-aut-mei=Masako
kn-aut-name=大森昌子
kn-aut-sei=大森
kn-aut-mei=昌子
aut-affil-num=5
ORCID=
en-aut-name=IhaSigemichi
en-aut-sei=Iha
en-aut-mei=Sigemichi
kn-aut-name=伊波茂道
kn-aut-sei=伊波
kn-aut-mei=茂道
aut-affil-num=6
ORCID=
en-aut-name=HongoToshie
en-aut-sei=Hongo
en-aut-mei=Toshie
kn-aut-name=本後登志江
kn-aut-sei=本後
kn-aut-mei=登志江
aut-affil-num=7
ORCID=
en-aut-name=HenmiNoriko
en-aut-sei=Henmi
en-aut-mei=Noriko
kn-aut-name=逸見典子
kn-aut-sei=逸見
kn-aut-mei=典子
aut-affil-num=8
ORCID=
en-aut-name=MakabeMikio
en-aut-sei=Makabe
en-aut-mei=Mikio
kn-aut-name=真壁幹夫
kn-aut-sei=真壁
kn-aut-mei=幹夫
aut-affil-num=9
ORCID=
en-aut-name=NogamiHiromi
en-aut-sei=Nogami
en-aut-mei=Hiromi
kn-aut-name=野上浩實
kn-aut-sei=野上
kn-aut-mei=浩實
aut-affil-num=10
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器外科学
affil-num=5
en-affil=
kn-affil=岡山大学病院 病理診断科
affil-num=6
en-affil=
kn-affil=岡山大福クリニック
affil-num=7
en-affil=
kn-affil=岡山大福クリニック
affil-num=8
en-affil=
kn-affil=岡山大福クリニック
affil-num=9
en-affil=
kn-affil=岡山中央病院
affil-num=10
en-affil=
kn-affil=野上病院
en-keyword=嚢胞内乳癌(intracystic breast cancer)
kn-keyword=嚢胞内乳癌(intracystic breast cancer)
en-keyword=術前化学療法(neoadjuvant chemotherapy)
kn-keyword=術前化学療法(neoadjuvant chemotherapy)
en-keyword=組織学的完全奏功(pahthological CR)
kn-keyword=組織学的完全奏功(pahthological CR)
END
start-ver=1.4
cd-journal=joma
no-vol=126
cd-vols=
no-issue=1
article-no=
start-page=25
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=20140401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Evaluation of a one-step nucleic acid amplification (OSNA) assay for sentinel lymph node metastases in early breast cancer
kn-title=早期乳癌におけるOne-step Nucleic Acid Amplification(OSNA)法によるセンチネルリンパ節転移診断の検討
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract= Introduction: The one-step nucleic acid amplification (OSNA) assay is a new method to detect sentinel lymph node (SLN) metastases using cytokeratin 19 (CK19) mRNA in early breast cancer. Here we retrospectively analyzed the advantages and disadvantages of the OSNA assay.
Methods: In a trial period, SLNs were divided into two sections, and we examined one side using the OSNA assay. The other side was examined by pathologists. After this period, we examined whole SLNs using only the OSNA assay. The patients with positive nodes by OSNA assay and/or pathology required axillary dissection.
Results: We examined 27 primary breast cancer patients (36 SLNs) during the trial period. The overall concordance rate between the OSNA assay and pathology results was 91%. In the later period, 157 patients (217 SLNs) were examined. The CK19-positive rate obtained by the OSNA assay was 16.5% (macrometastases OSNA (++) : 7.2%, micrometastases OSNA (+) : 9.2%). The non-SLN positive rate among the CK19-positivecases was 23%. The OSNA assay's false negative was one case in which the expression of CK-19 on the primary tumor and lymph node was not detected.
Conclusions: Our OSNA assay results were comparable to those obtained using a conventional pathological technique. Pathologists and laboratory technicians could save time and effort by using the OSNA assay when seeking the precise diagnosis during surgery.
en-copyright=
kn-copyright=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=溝尾妙子
kn-aut-sei=溝尾
kn-aut-mei=妙子
aut-affil-num=1
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=枝園忠彦
kn-aut-sei=枝園
kn-aut-mei=忠彦
aut-affil-num=2
ORCID=
en-aut-name=ItoMaiko
en-aut-sei=Ito
en-aut-mei=Maiko
kn-aut-name=伊藤麻衣子
kn-aut-sei=伊藤
kn-aut-mei=麻衣子
aut-affil-num=3
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=野上智弘
kn-aut-sei=野上
kn-aut-mei=智弘
aut-affil-num=4
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=岩本高行
kn-aut-sei=岩本
kn-aut-mei=高行
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=6
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=平成人
kn-aut-sei=平
kn-aut-mei=成人
aut-affil-num=7
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=8
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=土井原博義
kn-aut-sei=土井原
kn-aut-mei=博義
aut-affil-num=9
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=2
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=3
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=4
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=5
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=6
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=7
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=8
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
affil-num=9
en-affil=
kn-affil=岡山大学病院 乳腺・内分泌外科
en-keyword=OSNA法(OSNA method)
kn-keyword=OSNA法(OSNA method)
en-keyword=センチネルリンパ節(sentinel lymph node)
kn-keyword=センチネルリンパ節(sentinel lymph node)
en-keyword=micrometastases
kn-keyword=micrometastases
en-keyword=CK-19
kn-keyword=CK-19
END
start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=2
article-no=
start-page=123
end-page=125
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2006
dt-pub=20060901
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Duct lavage cytology for the detection of breast cancer: report of a case
kn-title=乳管洗浄細胞診が診断に有効であった乳癌の一例
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although many modalities have been established to diagnose breast cancers, it is sometimes difficult to reveal nonpalpable cases. Duct lavage cytology was originally established to reveal groups at high risk for breast cancers by detecting metaplastic ductal cells. We report here a case where duct lavage was useful for revealing a small cancer that had been undetected by repeated bloody nipple discharge and cytological examinations. Duct lavage cytology may be of use in cases where nipple discharge of unknown origin persists.
en-copyright=
kn-copyright=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=1
ORCID=
en-aut-name=TabuchiYoko
en-aut-sei=Tabuchi
en-aut-mei=Yoko
kn-aut-name=田渕陽子
kn-aut-sei=田渕
kn-aut-mei=陽子
aut-affil-num=2
ORCID=
en-aut-name=OnoRyoko
en-aut-sei=Ono
en-aut-mei=Ryoko
kn-aut-name=小野亮子
kn-aut-sei=小野
kn-aut-mei=亮子
aut-affil-num=3
ORCID=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=今田孝子
kn-aut-sei=今田
kn-aut-mei=孝子
aut-affil-num=4
ORCID=
en-aut-name=UmeokaTatsuo
en-aut-sei=Umeoka
en-aut-mei=Tatsuo
kn-aut-name=梅岡達生
kn-aut-sei=梅岡
kn-aut-mei=達生
aut-affil-num=5
ORCID=
en-aut-name=WatanabeNaoki
en-aut-sei=Watanabe
en-aut-mei=Naoki
kn-aut-name=渡辺直樹
kn-aut-sei=渡辺
kn-aut-mei=直樹
aut-affil-num=6
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=7
ORCID=
en-aut-name=MatsukawaHiroyosi
en-aut-sei=Matsukawa
en-aut-mei=Hiroyosi
kn-aut-name=松川啓義
kn-aut-sei=松川
kn-aut-mei=啓義
aut-affil-num=8
ORCID=
en-aut-name=NaomotoYoshio
en-aut-sei=Naomoto
en-aut-mei=Yoshio
kn-aut-name=猶本良夫
kn-aut-sei=猶本
kn-aut-mei=良夫
aut-affil-num=9
ORCID=
en-aut-name=TanakaNoriaki
en-aut-sei=Tanaka
en-aut-mei=Noriaki
kn-aut-name=田中紀章
kn-aut-sei=田中
kn-aut-mei=紀章
aut-affil-num=10
ORCID=
en-aut-name=YanaiHiroyuki
en-aut-sei=Yanai
en-aut-mei=Hiroyuki
kn-aut-name=柳井広之
kn-aut-sei=柳井
kn-aut-mei=広之
aut-affil-num=11
ORCID=
en-aut-name=OmoriMasako
en-aut-sei=Omori
en-aut-mei=Masako
kn-aut-name=大森昌子
kn-aut-sei=大森
kn-aut-mei=昌子
aut-affil-num=12
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=10
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=11
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 病理部
affil-num=12
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 病理部
en-keyword=乳管洗浄細胞診 (Ductal lavage cytology)
kn-keyword=乳管洗浄細胞診 (Ductal lavage cytology)
en-keyword=乳癌 (breast cancer)
kn-keyword=乳癌 (breast cancer)
en-keyword=診断 (diagnosis)
kn-keyword=診断 (diagnosis)
END
start-ver=1.4
cd-journal=joma
no-vol=118
cd-vols=
no-issue=2
article-no=
start-page=119
end-page=121
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2006
dt-pub=20060901
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Discrepancies between pathological examination and imaging analysis after primary systemic chemotherapy for breast cancer: report of two cases
kn-title=乳癌術前化学療法の効果判定における画像診断 われわれが経験した病理判定と画像診断の不一致症例について
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Primary systemic chemotherapy (PSC) in breast cancer prolongs disease-free survival in patients who have obtained pathological complete remission (pCR). In combination with pathological examination, CT and MRI have been used to
evaluate the efficacy of PSC, they generally coincide well with pathological evaluation. We here present two cases showing discrepancies between pathological examination and imaging analysis after PSC in breast cancer. We should
keep such discrepancies in mind to determine the ideal treatment after PSC. An accurate method of evaluating cellular damage by PSC is needed.
en-copyright=
kn-copyright=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=1
ORCID=
en-aut-name=TabuchiYoko
en-aut-sei=Tabuchi
en-aut-mei=Yoko
kn-aut-name=田渕陽子
kn-aut-sei=田渕
kn-aut-mei=陽子
aut-affil-num=2
ORCID=
en-aut-name=ItoMitsuya
en-aut-sei=Ito
en-aut-mei=Mitsuya
kn-aut-name=伊藤充矢
kn-aut-sei=伊藤
kn-aut-mei=充矢
aut-affil-num=3
ORCID=
en-aut-name=OnoRyoko
en-aut-sei=Ono
en-aut-mei=Ryoko
kn-aut-name=小野亮子
kn-aut-sei=小野
kn-aut-mei=亮子
aut-affil-num=4
ORCID=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=今田孝子
kn-aut-sei=今田
kn-aut-mei=孝子
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=6
ORCID=
en-aut-name=MatsukawaHiroyosi
en-aut-sei=Matsukawa
en-aut-mei=Hiroyosi
kn-aut-name=松川啓義
kn-aut-sei=松川
kn-aut-mei=啓義
aut-affil-num=7
ORCID=
en-aut-name=OhmoriMasako
en-aut-sei=Ohmori
en-aut-mei=Masako
kn-aut-name=大森昌子
kn-aut-sei=大森
kn-aut-mei=昌子
aut-affil-num=8
ORCID=
en-aut-name=YanaiHiroyuki
en-aut-sei=Yanai
en-aut-mei=Hiroyuki
kn-aut-name=柳井広之
kn-aut-sei=柳井
kn-aut-mei=広之
aut-affil-num=9
ORCID=
en-aut-name=NaomotoYoshio
en-aut-sei=Naomoto
en-aut-mei=Yoshio
kn-aut-name=猶本良夫
kn-aut-sei=猶本
kn-aut-mei=良夫
aut-affil-num=10
ORCID=
en-aut-name=TanakaNoriaki
en-aut-sei=Tanaka
en-aut-mei=Noriaki
kn-aut-name=田中紀章
kn-aut-sei=田中
kn-aut-mei=紀章
aut-affil-num=11
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=2
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=3
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=4
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=5
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=6
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=7
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=8
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 病理部
affil-num=9
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 病理部
affil-num=10
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
affil-num=11
en-affil=
kn-affil=岡山大学医学部・歯学部附属病院 消化器腫瘍外科
en-keyword=術前化学療法(Primary Systemic Chemotherapy)
kn-keyword=術前化学療法(Primary Systemic Chemotherapy)
en-keyword=画像診断(Imaging Analysis)
kn-keyword=画像診断(Imaging Analysis)
en-keyword=MRI
kn-keyword=MRI
en-keyword=CT
kn-keyword=CT
END
start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=1
article-no=
start-page=11
end-page=19
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202302
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Safety and Efficacy of a Well-Fitting Brassiere after Breast Reconstruction: A Qualitative Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The importance of a well-fitted, comfortable brassiere to overall quality of life after breast reconstruction has not been evaluated. Our aim was to determine the impact of a semi-customized brassiere on patients’ health-related quality of life after breast reconstruction. The subjects were prospective patients with mastectomy who were to undergo immediate or delayed breast reconstruction at our hospital. After surgery, a professional bra fitter sized each patient for a semi-customized brassiere and provided follow-up consultations. A self-reported questionnaire on breast aesthetics, postoperative pain, and satisfaction was used to assess the primary outcomes. Data were prospectively collected at baseline (before surgery) and at 1, 3, 6, and 12 months after surgery and analyzed. Forty-six patients (50 breasts) were included in the analysis. Consistent wearing of the brassiere reduced pain (p<0.05), with good overall satisfaction (p<0.001). Aesthetic scores on breast shape and size were higher with than without the custom brassiere at 3 months (p=0.02) and 6 months (p=0.03) after surgery. Wearing the brassiere reduced anxiety at all time points of measurement. A well-fitting brassiere ensured safety and provided a high degree of satisfaction without anxiety for patients after breast reconstruction.
en-copyright=
kn-copyright=
en-aut-name=WatanabeSatoko
en-aut-sei=Watanabe
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=SaigaMiho
en-aut-sei=Saiga
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=KimataYoshihiro
en-aut-sei=Kimata
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
affil-num=1
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=
affil-num=2
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=Department of General Surgery, Okayama Saiseikai General Hospital
kn-affil=
affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
affil-num=7
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=
en-keyword=breast reconstruction
kn-keyword=breast reconstruction
en-keyword=mastectomy
kn-keyword=mastectomy
en-keyword=brassiere
kn-keyword=brassiere
en-keyword=professional bra fitter
kn-keyword=professional bra fitter
END
start-ver=1.4
cd-journal=joma
no-vol=69
cd-vols=
no-issue=5
article-no=
start-page=291
end-page=299
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=201510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer:NACED-Randomized Multicenter Phase II Trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
en-copyright=
kn-copyright=
en-aut-name=SugiuKumi
en-aut-sei=Sugiu
en-aut-mei=Kumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KellyCatherine M.
en-aut-sei=Kelly
en-aut-mei=Catherine M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=WatanabeNaoki
en-aut-sei=Watanabe
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=ItohMitsuya
en-aut-sei=Itoh
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=HigakiKenji
en-aut-sei=Higaki
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=ImadaTakako
en-aut-sei=Imada
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=YuasaTakeshi
en-aut-sei=Yuasa
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=OmoriMasako
en-aut-sei=Omori
en-aut-mei=Masako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=SonobeHiroshi
en-aut-sei=Sonobe
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
affil-num=1
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=2
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=3
en-affil=
kn-affil=Department of Oncology, Mater Misericordiae University Hospital
affil-num=4
en-affil=
kn-affil=Department of Surgery, Chugoku Central Hospital
affil-num=5
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=6
en-affil=
kn-affil=Department of Breast Surgery, Hiroshima City Hospital
affil-num=7
en-affil=
kn-affil=Department of Breast Surgery, Hiroshima City Hospita
affil-num=8
en-affil=
kn-affil=Department of Breast Surgery, Hiroshima City Hospital
affil-num=9
en-affil=
kn-affil=Department of Surgery, Okayama Central Hospital
affil-num=10
en-affil=
kn-affil=Department of Surgery, Himeji Red Cross Hospital
affil-num=11
en-affil=
kn-affil=Department of Pathology, Okayama University Hospital
affil-num=12
en-affil=
kn-affil=Department of Pathology, Chugoku Central Hospital
affil-num=13
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
affil-num=14
en-affil=
kn-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science b Department of Breast and Endocrine Surgery, Okayama University Hospital
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=neoadjuvant chemotherapy
kn-keyword=neoadjuvant chemotherapy
en-keyword=concurrent hormone therapy
kn-keyword=concurrent hormone therapy
en-keyword=estrogen receptor positive
kn-keyword=estrogen receptor positive
en-keyword=tumor response
kn-keyword=tumor response
END
start-ver=1.4
cd-journal=joma
no-vol=122
cd-vols=
no-issue=1
article-no=
start-page=17
end-page=25
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20100401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits an anticancer effect in esophageal adenocarcinoma in vitro and in vivo
kn-title=Focal adhesion kinase (FAK) と Insulin-like growth factor-I receptor (IGF-IR) に対するデュアルチロシンキナーゼ阻害剤の食道腺癌における抗腫瘍効果
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=WatanabeNobuyuki
en-aut-sei=Watanabe
en-aut-mei=Nobuyuki
kn-aut-name=渡辺信之
kn-aut-sei=渡辺
kn-aut-mei=信之
aut-affil-num=1
ORCID=
en-aut-name=TakaokaMunenori
en-aut-sei=Takaoka
en-aut-mei=Munenori
kn-aut-name=岡宗徳
kn-aut-sei=岡
kn-aut-mei=宗徳
aut-affil-num=2
ORCID=
en-aut-name=SakuramaKazufumi
en-aut-sei=Sakurama
en-aut-mei=Kazufumi
kn-aut-name=櫻間一史
kn-aut-sei=櫻間
kn-aut-mei=一史
aut-affil-num=3
ORCID=
en-aut-name=TomonoYasuko
en-aut-sei=Tomono
en-aut-mei=Yasuko
kn-aut-name=友野靖子
kn-aut-sei=友野
kn-aut-mei=靖子
aut-affil-num=4
ORCID=
en-aut-name=HatakeyamaShinji
en-aut-sei=Hatakeyama
en-aut-mei=Shinji
kn-aut-name=畠山慎二
kn-aut-sei=畠山
kn-aut-mei=慎二
aut-affil-num=5
ORCID=
en-aut-name=OhmoriOsamu
en-aut-sei=Ohmori
en-aut-mei=Osamu
kn-aut-name=大森修
kn-aut-sei=大森
kn-aut-mei=修
aut-affil-num=6
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=元木崇之
kn-aut-sei=元木
kn-aut-mei=崇之
aut-affil-num=7
ORCID=
en-aut-name=ShirakawaYasuhiro
en-aut-sei=Shirakawa
en-aut-mei=Yasuhiro
kn-aut-name=白川靖博
kn-aut-sei=白川
kn-aut-mei=靖博
aut-affil-num=8
ORCID=
en-aut-name=YamatsujiTomoki
en-aut-sei=Yamatsuji
en-aut-mei=Tomoki
kn-aut-name=山辻知樹
kn-aut-sei=山辻
kn-aut-mei=知樹
aut-affil-num=9
ORCID=
en-aut-name=HaisaMinoru
en-aut-sei=Haisa
en-aut-mei=Minoru
kn-aut-name=羽井佐実
kn-aut-sei=羽井佐
kn-aut-mei=実
aut-affil-num=10
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=松岡順治
kn-aut-sei=松岡
kn-aut-mei=順治
aut-affil-num=11
ORCID=
en-aut-name=BeerDavid G.
en-aut-sei=Beer
en-aut-mei=David G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=NagatsukaHitoshi
en-aut-sei=Nagatsuka
en-aut-mei=Hitoshi
kn-aut-name=長塚仁
kn-aut-sei=長塚
kn-aut-mei=仁
aut-affil-num=13
ORCID=
en-aut-name=TanakaNoriaki
en-aut-sei=Tanaka
en-aut-mei=Noriaki
kn-aut-name=田中紀章
kn-aut-sei=田中
kn-aut-mei=紀章
aut-affil-num=14
ORCID=
en-aut-name=NaomotoYoshio
en-aut-sei=Naomoto
en-aut-mei=Yoshio
kn-aut-name=猶本良夫
kn-aut-sei=猶本
kn-aut-mei=良夫
aut-affil-num=15
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=4
en-affil=
kn-affil=重井医学研究所
affil-num=5
en-affil=
kn-affil=ノバルティスファーマ 筑波研究所
affil-num=6
en-affil=
kn-affil=ノバルティスファーマ 筑波研究所
affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=10
en-affil=
kn-affil=岡山市立市民病院 外科
affil-num=11
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=12
en-affil=
kn-affil=ミシガン大学 胸部外科
affil-num=13
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 口腔病理学
affil-num=14
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
affil-num=15
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科 消化器・腫瘍外科学
en-keyword=focal adhesion kinase (FAK)
kn-keyword=focal adhesion kinase (FAK)
en-keyword=バレット食道癌
kn-keyword=バレット食道癌
en-keyword=FAK阻害剤
kn-keyword=FAK阻害剤
END
start-ver=1.4
cd-journal=joma
no-vol=143
cd-vols=
no-issue=2
article-no=
start-page=403
end-page=409
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=201401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/PR-negative (n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR > 10 % positive. ESR1 expression was high in 25 % of ER-negative/PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.
en-copyright=
kn-copyright=
en-aut-name=ItohMitsuya
en-aut-sei=Itoh
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=NiikuraNaoki
en-aut-sei=Niikura
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=HayashiNaoki
en-aut-sei=Hayashi
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=HigakiKenji
en-aut-sei=Higaki
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=SymmansW. Fraser
en-aut-sei=Symmans
en-aut-mei=W. Fraser
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=PusztaiLajos
en-aut-sei=Pusztai
en-aut-mei=Lajos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
affil-num=1
en-affil=
kn-affil=Okayama Univ
affil-num=2
en-affil=
kn-affil=Okayama Univ
affil-num=3
en-affil=
kn-affil=Okayama Univ
affil-num=4
en-affil=
kn-affil=Okayama Univ
affil-num=5
en-affil=
kn-affil=Okayama Univ
affil-num=6
en-affil=
kn-affil=Okayama Univ
affil-num=7
en-affil=
kn-affil=Okayama Univ
affil-num=8
en-affil=
kn-affil=Tokai Univ
affil-num=9
en-affil=
kn-affil=St Lukes Int Hosp
affil-num=10
en-affil=
kn-affil=Hiroshima City Hosp
affil-num=11
en-affil=
kn-affil=Hiroshima City Hosp
affil-num=12
en-affil=
kn-affil=Okayama Univ
affil-num=13
en-affil=
kn-affil=Okayama Univ
affil-num=14
en-affil=
kn-affil=Univ Texas MD Anderson Canc Ctr
affil-num=15
en-affil=
kn-affil=Yale Univ
en-keyword=Estrogen receptor
kn-keyword=Estrogen receptor
en-keyword=Progesteron receptor
kn-keyword=Progesteron receptor
en-keyword=cDNA microarray
kn-keyword=cDNA microarray
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Hormone therapy
kn-keyword=Hormone therapy
END
start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20131201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of lifestyle and single nucleotide polymorphisms on breast cancer risk: a case-control study in Japanese women
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Lifestyle factors, including food and nutrition, physical activity, body composition and reproductive factors, and single nucleotide polymorphisms (SNPs) are associated with breast cancer risk, but few studies of these factors have been performed in the Japanese population. Thus, the goals of this study were to validate the association between reported SNPs and breast cancer risk in the Japanese population and to evaluate the effects of SNP genotypes and lifestyle factors on breast cancer risk.
Methods: A case-control study in 472 patients and 464 controls was conducted from December 2010 to November 2011. Lifestyle was examined using a self-administered questionnaire. We analyzed 16 breast cancer-associated SNPs based on previous GWAS or candidate-gene association studies. Age or multivariate-adjusted odds ratios (OR) and 95% confidence intervals (95% CI) were estimated from logistic regression analyses.
Results: High BMI and current or former smoking were significantly associated with an increased breast cancer risk, while intake of meat, mushrooms, yellow and green vegetables, coffee, and green tea, current leisure-time exercise, and education were significantly associated with a decreased risk. Three SNPs were significantly associated with a breast cancer risk in multivariate analysis: rs2046210 (per allele OR = 1.37 [95% CI: 1.11-1.70]), rs3757318 (OR = 1.33[1.05-1.69]), and rs3803662 (OR = 1.28 [1.07-1.55]). In 2046210 risk allele carriers, leisure-time exercise was associated with a significantly decreased risk for breast cancer, whereas current smoking and high BMI were associated with a significantly decreased risk in non-risk allele carriers.
Conclusion: In Japanese women, rs2046210 and 3757318 located near the ESR1 gene are associated with a risk of breast cancer, as in other Asian women. However, our findings suggest that exercise can decrease this risk in allele carriers.
en-copyright=
kn-copyright=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=NishiyamaKeiko
en-aut-sei=Nishiyama
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=IshiharaSetsuko
en-aut-sei=Ishihara
en-aut-mei=Setsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=KawaiHiroshi
en-aut-sei=Kawai
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=KawasakiKensuke
en-aut-sei=Kawasaki
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=IshibeYouichi
en-aut-sei=Ishibe
en-aut-mei=Youichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=OgasawaraYutaka
en-aut-sei=Ogasawara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=KomoikeYoshifumi
en-aut-sei=Komoike
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=MiyoshiShinichiro
en-aut-sei=Miyoshi
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
affil-num=1
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=2
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=3
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=4
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=5
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=6
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=7
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=8
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=9
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
affil-num=10
en-affil=
kn-affil=Okayama Saiseikai Gen Hosp, Dept Radiol
affil-num=11
en-affil=
kn-affil=Okayama Rousai Hosp, Dept Breast Surg
affil-num=12
en-affil=
kn-affil=Kagawa Prefectural Canc Detect Ctr, Dept Breast Surg
affil-num=13
en-affil=
kn-affil=Mizushima Kyodo Hosp, Dept Breast Surg
affil-num=14
en-affil=
kn-affil=Dept Breast & Endocrinol Surg
affil-num=15
en-affil=
kn-affil=Kinki Univ Hosp, Fac Med
affil-num=16
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg
en-keyword=Japanese women
kn-keyword=Japanese women
en-keyword=Asian
kn-keyword=Asian
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Lifestyle
kn-keyword=Lifestyle
en-keyword=Leisure-time exercise
kn-keyword=Leisure-time exercise
en-keyword=Parity
kn-keyword=Parity
en-keyword=Single nucleotide polymorphisms
kn-keyword=Single nucleotide polymorphisms
en-keyword=rs2046210
kn-keyword=rs2046210
en-keyword=rs3757318
kn-keyword=rs3757318
en-keyword=ESR1
kn-keyword=ESR1
END
start-ver=1.4
cd-journal=joma
no-vol=69
cd-vols=
no-issue=6
article-no=
start-page=333
end-page=338
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2015
dt-pub=201512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Correlation between 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography and Clinicopathological Features in Invasive Ductal Carcinoma of the Breast
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We evaluated the usefulness of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) examinations to predict the pathological features in primary breast cancer. In particular, we evaluated the correlation between the maximum standardized uptake values (SUVmax) obtained by 18F-FDG PET/CT and the Ki67 expression in estrogen receptor (ER)-positive invasive ductal carcinoma (IDC). Primary IDC patients operated between March 2009 and July 2013 at Okayama University Hospital were enrolled. We evaluated the correlations between the SUVmax and age, postoperative pT, histological grade, lymph vascular invasion, status of hormone receptor, human epidermal growth factor receptor 2 (HER2), Ki67 expression and node status. The Ki67 expression was classified as high (>14%) versus low (<14%). We enrolled 138 patients with IDC. Their median SUVmax was 3.85 (range:0-52.57). In a univariate analysis, the SUVmax was significantly related to age, pT, histological grade, lymphovascular invasion, hormone receptor status, HER2 status, node status and Ki67. In the 113 patients with ER-positive IDC, there was a significant correlation between Ki67 and SUVmax (p=0.0030). The preoperative 18F-FDG PET/CT results of IDC patients had significant relationships with pathological status parameters. The determination of the preoperative SUVmax might help classify Luminal A and Luminal B patients among luminal-type breast cancer patients.
en-copyright=
kn-copyright=
en-aut-name=ItoMaiko
en-aut-sei=Ito
en-aut-mei=Maiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KajiMitsumasa
en-aut-sei=Kaji
en-aut-mei=Mitsumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=MiyoshiShinichiro
en-aut-sei=Miyoshi
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
affil-num=1
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=2
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=3
en-affil=
kn-affil=Okayama Diagnostic Imaging Center
affil-num=4
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=5
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=6
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=7
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=8
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=9
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=10
en-affil=
kn-affil=Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=invasive ductal carcinoma
kn-keyword=invasive ductal carcinoma
en-keyword=18F-fluorodeoxyglucose positron emission tomography/computed tomography
kn-keyword=18F-fluorodeoxyglucose positron emission tomography/computed tomography
en-keyword=maximum standardized uptake values
kn-keyword=maximum standardized uptake values
en-keyword=clinicopathological features
kn-keyword=clinicopathological features
END
start-ver=1.4
cd-journal=joma
no-vol=67
cd-vols=
no-issue=3
article-no=
start-page=145
end-page=151
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=201306
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between Mammographic Breast Density and Lifestyle in Japanese Women
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A high mammographic breast density is considered to be a risk factor for breast cancer. However, only a small number of studies on the association between breast density and lifestyle have been performed. A cross-sectional study was performed using a survey with 29 questions on life history and lifestyle. The breast density on mammography was classified into 4 categories following the BI-RADS criteria. The subjects were 522 women with no medical history of breast cancer. The mean age was 53.3 years old. On multivariate analysis, only BMI was a significant factor determining breast density in premenopausal women (parameter estimate, −0.403;p value, 0.0005), and the density decreased as BMI rose. In postmenopausal women, BMI (parameter estimate, −0.196;p value, 0.0143) and number of deliveries (parameter estimate, −0.388;p value, 0.0186) were significant factors determining breast density;breast density decreased as BMI and number of deliveries increased. Only BMI and number of deliveries were identified as factors significantly influencing breast density. BMI was inversely correlated with breast density before and after menopause, whereas the influence of number of deliveries on breast density was significant only in postmenopausal women in their 50 and 60s.
en-copyright=
kn-copyright=
en-aut-name=IshiharaSetsuko
en-aut-sei=Ishihara
en-aut-mei=Setsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KawasakiKensuke
en-aut-sei=Kawasaki
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=IshibeYouichi
en-aut-sei=Ishibe
en-aut-mei=Youichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=NishiyamaKeiko
en-aut-sei=Nishiyama
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=KomoikeYoshifumi
en-aut-sei=Komoike
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=SatoShuhei
en-aut-sei=Sato
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=KanazawaSusumu
en-aut-sei=Kanazawa
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
affil-num=1
en-affil=
kn-affil=Department of Radiology, Okayama Saiseikai General Hospital
affil-num=2
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=3
en-affil=
kn-affil=Department of Surgery, Kagawa Prefectural Cancer Detection Center
affil-num=4
en-affil=
kn-affil=Department of Surgery, Mizushima Kyodo Hospital
affil-num=5
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=6
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=7
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=8
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=9
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=10
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=11
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=12
en-affil=
kn-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
affil-num=13
en-affil=
kn-affil=Department of Surgery, Kinki University Hospital
affil-num=14
en-affil=
kn-affil=Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
affil-num=15
en-affil=
kn-affil=Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=mammographic breast density
kn-keyword=mammographic breast density
en-keyword=life style
kn-keyword=life style
en-keyword=body mass index
kn-keyword=body mass index
END
start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=3
article-no=
start-page=230
end-page=236
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=201303
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model.
First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I alpha (HIF-1 alpha), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 +/- 722.0; temsirolimus, 599.2 +/- 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024).
These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.
en-copyright=
kn-copyright=
en-aut-name=NishikawaToshio
en-aut-sei=Nishikawa
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TakaokaMunenori
en-aut-sei=Takaoka
en-aut-mei=Munenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=OharaToshiaki
en-aut-sei=Ohara
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=TomonoYasuko
en-aut-sei=Tomono
en-aut-mei=Yasuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=HaoHuifang
en-aut-sei=Hao
en-aut-mei=Huifang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=BaoXiaohong
en-aut-sei=Bao
en-aut-mei=Xiaohong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=FukazawaTakuya
en-aut-sei=Fukazawa
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=WangZhigang
en-aut-sei=Wang
en-aut-mei=Zhigang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=SakuramaKazufumi
en-aut-sei=Sakurama
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=FujiwaraYasuhiro
en-aut-sei=Fujiwara
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=ShirakawaYasuhiro
en-aut-sei=Shirakawa
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=YamatsujiTomoki
en-aut-sei=Yamatsuji
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=TanakaNoriaki
en-aut-sei=Tanaka
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=NaomotoYoshio
en-aut-sei=Naomoto
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
affil-num=1
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=2
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=3
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=4
en-affil=
kn-affil=Shigei Med Res Inst
affil-num=5
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=6
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=7
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=8
en-affil=
kn-affil=Inner Mongolia Univ, Coll Life Sci, Dept Biol
affil-num=9
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=10
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=11
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=12
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=13
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=14
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=15
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
affil-num=16
en-affil=
kn-affil=Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol Surg & Surg Oncol
en-keyword=temsirolimus
kn-keyword=temsirolimus
en-keyword=esophageal cancer
kn-keyword=esophageal cancer
en-keyword=mTOR
kn-keyword=mTOR
en-keyword=prolonged survival
kn-keyword=prolonged survival
en-keyword=molecular-targeted therapy
kn-keyword=molecular-targeted therapy
END
start-ver=1.4
cd-journal=joma
no-vol=70
cd-vols=
no-issue=5
article-no=
start-page=425
end-page=427
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2016
dt-pub=201610
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Phase I Trial of 100mg/m2 Docetaxel in Patients with Advanced or Recurrent Breast Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer.
en-copyright=
kn-copyright=
en-aut-name=TamuraTomoki
en-aut-sei=Tamura
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=HirataTaizo
en-aut-sei=Hirata
en-aut-mei=Taizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=TabataMasahiro
en-aut-sei=Tabata
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=HamadaAkinobu
en-aut-sei=Hamada
en-aut-mei=Akinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=MotokiTakayuki
en-aut-sei=Motoki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=MizooTaeko
en-aut-sei=Mizoo
en-aut-mei=Taeko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=NogamiTomohiro
en-aut-sei=Nogami
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=MatsuokaJunji
en-aut-sei=Matsuoka
en-aut-mei=Junji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
affil-num=1
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
affil-num=2
en-affil=Department of Medical Oncology, National Hospital Organization Kure Medical Center
kn-affil=
affil-num=3
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Division of Clinical Pharmacology & Translational Research, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center
kn-affil=
affil-num=6
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=7
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=9
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=10
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=11
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=12
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
affil-num=13
en-affil=Department of Breast and Endocrinological Surgery, Okayama University Hospital
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=phase I trial
kn-keyword=phase I trial
en-keyword=docetaxel
kn-keyword=docetaxel
END